Pharmacogenetics of therapy in inflammatory bowel disease patients

Current Pharmacogenomics

Volumn 5, Issue 3, 2007, Pages 235-247

  Mendoza, J L ^a   Lana, R ^a   Diaz Rubio M ^a   de la Concha, E G ^a   Urcelay, E ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

5 Aminosalicylic acid; Azathioprine; Corticosteroids; Methotrexate; Thiopurine S methyltransferase; Ulcerative colitis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AZATHIOPRINE; BUDESONIDE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; TIOGUANINE;

ABDOMINAL PAIN; ACNE; ALLELE; ALLERGIC PNEUMONITIS; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE NECROSIS; CATARACT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; ENTERITIS; ENVIRONMENTAL FACTOR; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENE FUNCTION; GENE STRUCTURE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLUCOSE INTOLERANCE; HEPATITIS; HEREDITY; HUMAN; INFECTION SENSITIVITY; LIVER HYPERPLASIA; LIVER TOXICITY; LOW DRUG DOSE; MOOD DISORDER; MOON FACE; MYOPATHY; NAUSEA; NEUROTOXICITY; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PHARMACOGENETICS; PREDICTION; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 34648836576     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016007781669213     Document Type: Review

References (158)

1. Agnholt, J.; Kelsen, J.; Brandsborg, B.; Jakobsen, N. O. and Dahlerup, J. F. (2004) Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease-a possible target for infliximab treatment. Eur. J. Gastroenterol. Hepatol. 16, 649-655.
2. Ahmad, T.; Tamboli, C. P.; Jewell, D. and Colombel, J. F. (2004) Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126, 1533-1549.
3. Allorge, D.; Hamdan, R.; Broly, F.; Libersa, C. and Colombel, J. F. (2005) ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54, 565.
4. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I. and Gottesman, M. M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361-398.
5. Anglicheau, D.; Legendre, C. and Thervet, E. (2004) Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 78, 311-315.
6. Annese, V.; Valvano, M. R.; Palmieri, O.; Latiano, A.; Bossa, F. and Andriulli, A. (2006) Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J. Gastroenterol. 12, 3636-3644.
7. Ansari, A.; Hassan, C.; Duley, J.; Marinaki, A.; Shobowale-Bakre, E. M.; Seed, P.; Meenan, J.; Yim, A. and Sanderson, J. (2002) Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 1743-1750.
8. Armstrong, V. W.; Shipkova, M.; Von Ahsen, N. and Oellerich, M. (2004) Analytic aspects of monitoring therapy with thiopurine medications. Ther. Drug Monit. 26, 220-226.
9. Arnott, I. D.; Mcneill, G. and Satsangi, J. (2003) An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17, 1451-1457.
10. Baert, F. and Rutgeerts, P. (2001) 6-Thioguanine: a naked bullet? (Or how pharmacogenomics can make old drugs brand new). Inflamm. Bowel Dis. 7, 190-191.
11. Bantel, H.; Schmitz, M. L.; Raible, A.; Gregor, M. and Schulze-Osthoff, K. (2002) Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. FASEB J. 16, 1832-1834.
12. Baron, T. H.; Truss, C. D. and Elson, C. O. (1993) Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig. Dis. Sci. 38, 1851-1856.
13. Berkun, Y.; Levartovsky, D.; Rubinow, A.; Orbach, H.; Aamar, S.; Grenader, T.; Abou Atta, I.; Mevorach, D.; Friedman, G. and Ben-Yehuda, A. (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis. 63, 1227-1231.
14. Bonaz, B.; Boitard, J.; Marteau, P.; Lemann, M.; Coffin, B.; Flourie, B.; Belaiche, J.; Cadiot, G.; Metman, E. H.; Cortot, A. and Colombel, J. F. (2003) Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment. Pharmacol. Ther. 18, 401-408.
15. Borruel, N.; Carol, M.; Casellas, F.; Antolin, M.; De Lara, F.; Espin, E.; Naval, J.; Guarner, F. and Malagelada, J. R. (2002) Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51, 659-664.
16. Brant, S. R.; Panhuysen, C. I.; Nicolae, D.; Reddy, D. M.; Bonen, D. K.; Karaliukas, R.; Zhang, L.; Swanson, E.; Datta, L. W.; Moran, T.; Ravenhill, G.; Duerr, R. H.; Achkar, J. P.; Karban, A. S. and Cho, J. H. (2003) MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet. 73, 1282-1292.
17. Carter, M. J.; Lobo, A. J. and Travis, S. P. (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53(Suppl. 5), V1-V16.
18. Cohen, R. D. (2002) Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy". Gastroenterology 122, 2082-2084; discussion 2084.
19. Cohen, R. D. (2006) Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 24, 465-474.
20. Colombel, J. F.; Ferrari, N.; Debuysere, H.; Marteau, P.; Gendre, J. P.; Bonaz, B.; Soule, J. C.; Modigliani, R.; Touze, Y.; Catala, P.; Libersa, C. and Broly, F. (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118, 1025-1030.
21. Connell, W. R.; Kamm, M. A.; Ritchie, J. K. and Lennard-Jones, J. E. (1993) Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34, 1081-1085.
22. Cuffari, C.; Hunt, S. and Bayless, T. M. (2000) Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment. Pharmacol. Ther. 14, 1009-1014.
23. Chen, Z. S.; Lee, K.; Walther, S.; Raftogianis, R. B.; Kuwano, M.; Zeng, H. and Kruh, G. D. (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62, 3144-3150.
24. Cheung, S. T. and Allan, R. N. (2003) Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Eur. J. Gastroenterol. Hepatol. 15, 1245-1247.
25. D'halluin, P. N.; Tribut, O.; Branger, B.; Lebreton, C.; Bretagne, J. F.; Bentue-Ferrer, D. and Heresbach, D. (2005) RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine. Gastroenterol. Clin. Biol. 29, 1264-1269.
26. De Boer, N. K.; Reinisch, W.; Teml, A.; Van Bodegraven, A. A.; Schwab, M.; Lukas, M.; Ochsenkuhn, T.; Petritsch, W.; Knoflach, P.; Almer, S.; Van Der Merwe, S. W.; Herrlinger, K. R.; Seiderer, J.; Vogelsang, H. and Mulder, C. J. (2006) 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 73, 25-31.
27. De Ridder, L.; Van Dieren, J. M.; Van Deventer, H. J.; Stokkers, P. C.; Van Der Woude, J. C.; Van Vuuren, A. J.; Benninga, M. A.; Escher, J. C. and Hommes, D. W. (2006) Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment. Pharmacol. Ther. 23, 1137-1141.
28. Derijks, L. J.; De Jong, D. J.; Gilissen, L. P.; Engels, L. G.; Hooymans, P. M.; Jansen, J. B. and Mulder, C. J. (2003) 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur. J. Gastroenterol. Hepatol. 15, 63-67.
29. Derijks, L. J.; Gilissen, L. P.; Engels, L. G.; Bos, L. P.; Bus, P. J.; Lohman, J. J.; Curvers, W. L.; Van Deventer, S. J.; Hommes, D. W. and Hooymans, P. M. (2004) Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther. Drug Monit. 26, 311-318.
30. Dervieux, T.; Furst, D.; Lein, D. O.; Capps, R.; Smith, K.; Walsh, M. and Kremer, J. (2004a) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50, 2766-2774.
31. Dervieux, T.; Greenstein, N. and Kremer, J. (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 54, 3095-3103.
32. Dervieux, T.; Kremer, J.; Lein, D. O.; Capps, R.; Barham, R.; Meyer, G.; Smith, K.; Caldwell, J. and Furst, D. E. (2004b) Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14, 733-739
33. Dideberg, V.; Louis, E.; Farnir, F.; Bertoli, S.; Vermeire, S.; Rutgeerts, P.; De Vos, M.; Van Gossum, A.; Belaiche, J. and Bouts, V. (2006a) Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet. Genomics 16, 369-373.
34. Dideberg, V.; Theatre, E.; Farnir, F.; Vermeire, S.; Rutgeerts, P.; Vos, M. D.; Belaiche, J.; Franchimont, D.; Gossum, A. V.; Louis, E. and Bouts, V. (2006b) The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet. Genomics 16, 727-734.
35. Dilger, K.; Schwab, M. and Fromm, M. F. (2004) Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm. Bowel Dis. 10, 578-583.
36. Doering, J.; Begue, B.; Lentze, M. J.; Rieux-Laucat, F.; Goulet, O.; Schmitz, J.; Cerf-Bensussan, N. and Ruemmele, F. M. (2004) Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 53, 1632-1638.
37. Dubinsky, M. C. (2003) Optimizing immunomodulator therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5, 506-511.
38. Dubinsky, M. C.; Feldman, E. J.; Abreu, M. T.; Targan, S. R. and Vasiliauskas, E. A. (2003a) Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am. J. Gastroenterol. 98, 1058-1063.
39. Dubinsky, M. C.; Lamothe, S.; Yang, H. Y.; Targan, S. R.; Sinnett, D.; Theoret, Y. and Seidman, E. G. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118, 705-713.
40. Dubinsky, M. C.; Vasiliauskas, E. A.; Singh, H.; Abreu, M. T.; Papadakis, K. A.; Tran, T.; Martin, P.; Vierling, J. M.; Geller, S. A.; Targan, S. R. and Poordad, F. F. (2003b) 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125, 298-303.
41. Dubinsky, M. C.; Yang, H.; Hassard, P. V.; Seidman, E. G.; Kam, L. Y.; Abreu, M. T.; Targan, S. R. and Vasiliauskas, E. A. (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122, 904-915.
42. Duerr, R. H.; Taylor, K. D.; Brant, S. R.; Rioux, J. D.; Silverberg, M. S.; Daly, M. J.; Steinhart, A. H.; Abraham, C.; Regueiro, M.; Griffiths, A.; Dassopoulos, T.; Bitton, A.; Yang, H.; Targan, S.; Datta, L. W.; Kismer, E. O.; Schumm, L. P.; Lee, A. T.; Gregersen, P. K.; Barmada, M. M.; Rotter, J. I.; Nicolae, D. L. and Cho, J. H. (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463.
43. Esters, N.; Vermeire, S.; Joossens, S.; Noman, M.; Louis, E.; Belaiche, J.; De Vos, M.; Van Gossum, A.; Pescatore, P.; Fiasse, R.; Pelckmans, P.; Reynaert, H.; Poulain, D.; Bossuyt, X. and Rutgeerts, P. (2002) Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am. J. Gastroenterol. 97, 1458-1462.
44. Evans, W. E. (2004) Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug Monit. 26, 186-191.
45. Farrell, R. J.; and Kelleher, D. (2003) Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 178, 339-346.
46. Farrell, R. J.; Menconi, M. J.; Keates, A. C. and Kelly, C. P. (2002) P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment Pharmacol. Ther. 16, 1021-1031.
47. Farrell, R. J.; Murphy, A.; Long, A.; Donnelly, S.; Cherikuri, A.; O'toole, D.; Mahmud, N.; Keeling, P. W.; Weir, D. G. and Kelleher, D. (2000) High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118, 279-288.
48. Feagan, B. G.; Fedorak, R. N.; Irvine, E. J.; Wild, G.; Sutherland, L.; Steinhart, A. H.; Greenberg, G. R.; Koval, J.; Wong, C. J.; Hopkins, M.; Hanauer, S. B. and Mcdonald, J. W. (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342, 1627-1632.
49. Feagan, B. G.; Rochon, J.; Fedorak, R. N.; Irvine, E. J.; Wild, G.; Sutherland, L.; Steinhart, A. H.; Greenberg, G. R.; Gillies, R.; Hopkins, M. and et al. (1995) Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 332, 292-297.
50. Flood, L.; Lofberg, R.; Stierna, P. and Wikstrom, A. C. (2001) Glucocorticoid receptor mRNA in patients with ulcerative cotitis: a study of responders and nonresponders to glucocorticosteroid therapy. Inflamm. Bowel Dis. 7, 202-209.
51. Fraser, A. G.; Orchard, T. R. and Jewell, D. P. (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50, 485-489.
52. Fretland, A. J.; Doll, M. A.; Leff, M. A. and Hein, D. W. (2001 a) Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics 11, 511-520.
53. Fretland, A. J.; Leff, M. A.; Doll, M. A. and Hein, D. W. (2001b) Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 11, 207-215.
54. Gearry, R. B. and Barclay, M. L. (2005) Azathioprine and 6-mercaptopurine pbarmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 20, 1149-1157.
55. Gearry, R. B.; Roberts, R. L.; Barclay, M. L. and Kennedy, M. A. (2004) Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14, 779-781.
56. Geller, S. A.; Dubinsky, M. C.; Poordad, F. F.; Vasiliauskas, E. A.; Cohen, A. H.; Abreu, M. T.; Tran, T.; Martin, P.; Vierling, J. M. and Targan, S. R. (2004) Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am. J. Surg. Pathol. 28, 1204-1211.
57. Gilissen, L. P.; Derijks, L. J.; Bos, L. P.; Verhoeven, H. M.; Bus, P. J.; Hooymans, P. M. and Engels, L. G. (2004) Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur. J. Gastroenterol. Hepatol. 16, 705-710.
58. Hampe, J.; Cuthbert, A.; Croucher, P. J.; Mirza, M. M.; Mascheretti, S.; Fisher, S.; Frenzel, H.; King, K.; Hasselmeyer, A.; Macpherson, A. J.; Bridget, S.; Van Deventer, S.; Forbes, A.; Nikolaus, S.; Lennard-Jones, J. E.; Foetsch, U. R.; Krawczak, M.; Lewis, C.; Schreiber, S. and Mathew, C. G. (2001) Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357, 1925-1928.
59. Hanauer, S. B. and Sandborn, W. (2001) Management of Crohn's disease in adults. Am. J. Gastroenterol. 96, 635-643.
60. Hein, D. W.; Doll, M. A.; Fretland, A. J.; Leff, M. A.; Webb, S. J.; Xiao, G. H.; Devanaboyina, U. S.; Nangju, N. A. and Feng, Y. (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9, 29-42.
61. Herrlinger, K. R.; Cummings, J. R.; Barnardo, M. C.; Schwab, M.; Ahmad, T. and Jewell, D. P. (2005) The pharmacogeneties of methotrexate in inflammatory bowel disease. Pharmarogenet. Genomics 15, 705-711.
62. Herrlinger, K. R.; Deibert P.; Schwab, M.; Kreisel, W.; Fischer, C.; Fellermann, K.; Stange, E. F.; Schoelmerich, J.; Fleig, W. E.; Ruhl, A.; Reirishagen, M. and Greinwald, R. (2003) Remission maintenance by tioguanine in chronic active Crohn's disease 6-thioguanine-efficacy and safety in chronic active Crohn's disease. Aliment. Pharmacol. Ther. 17, 1459-1464.
63. Hider, S. L.; Morgan, C.; Bell, E. and Bruce, I. N. (2003) Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with RA? Ann. Rheum. Dis. 62, 591; author reply 591-592.
64. Hlavaty, T.; Pierik, M.; Henckaerts, L.; Ferrante, M.; Joossens, S.; Van Schuerbeek, N.; Noman, M.; Rutgeerts, P. and Venneire, S. (2005) Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 22, 613-626.
65. Ho, G. T.; Moodie, F. M. and Satsangi, J. (2003) Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52, 759-766.
66. Ho, G. T.; Nimmo, E. R.; Tenesa, A.; Fennell, J.; Drummond, H.; Mowat, C.; Arnott, I. D. and Satsangi, J. (2005) Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128, 288-296.
67. Hoffmeyer, S.; Burk, O.; Von Richter, O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaumm, M. and Brinkmann, U. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478.
68. Honda, M.; Orii, F.; Ayabe, T.; Imai, S.; Ashida, T.; Obara, T. and Kohgo, Y. (2000) Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 118, 859-866.
69. Hopkins, M. M.; Ibarreta, D.; Gaisser, S.; Enzing, C. M.; Ryan, J.; Martin, P. A.; Lewis, G.; Detmar, S.; Van Den Akker-Van Marle, M. E.; Hedgecoe, A. M.; Nightingale, P.; Dreding, M.; Hartig, K. J.; Vullings, W. and Forde, T. (2006) Putting pharmacogenetics into practice. Nat. Biotechnol. 24, 403-410.
70. Hughes, L. B.; Beasley, T. M.; Patel, H.; Tiwari, H. K.; Morgan, S. L.; Baggott, J. E.; Saag, K. G.; Mcnicholl, J.; Moreland, L. W.; Alarcon, G. S. and Bridges, S. L., Jr. (2006) Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenctetahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1213-1218.
71. Hugot, J. P.; Chamaillard, M.; Zouali, H.; Lesage, S.; Cezard, J. P.; Belaiche, J.; Almer, S.; Tysk, C.; O'morain, C. A.; Gassull, M.; Binder, V.; Finkel, Y.; Cortot, A.; Modigliani, R.; Laurent-Puig, P.; Gower-Rousseau, C.; Macry, J.; Colombel, J. F.; Sahbatou, M. and Thomas, G. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603.
72. Kaskas, B. A.; Louis, E.; Hindorf, U.; Schaeffeler, E.; Deflandre, J.; Graepler, F.; Schmiegelow, K.; Gregor, M.; Zanger, U. M.; Eichelbaum, M. and Schwab, M. (2003) Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 52, 140-142.
73. Komatsu, M.; Kobayashi, D.; Saito, K.; Furuya, D.; Yagihashi, A.; Araake, H.; Tsuji, N.; Sakamaki, S.; Niitsu, Y. and Watanabe, N. (2001) Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin. Chem. 47, 1297-1301.
74. Kontoyiannis, D.; Pasparakis, M.; Pizarro, T. T.; Cominelli, F. and Kollias, G. (1999) Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387-398.
75. Kremer, J. M. (2006) Methotrexate pharmacogenomics. Ann. Rheum. Dis. 65, 1121-1123.
76. Krynetski, E. Y. and Evans, W. E. (2000) Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 61, 136-146.
77. Krynetski, E. Y.; Krynetskaia, N. F.; Yanishevski, Y. and Evans, W. E. (1995) Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol. Pharmacol. 47, 1141-1147.
78. Lennard, L. (1992) The clinical pharmacology of 6-mercaptopurine. Eur. J Clin. Pharmacol. 43, 329-339.
79. Lindqvist, M.; Haglund, S.; Almer, S.; Peterson, C.; Taipalensu, J.; Hertervig, E.; Lyrenas, E. and Soderkvist, P. (2004) Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmaeogrenetics 14, 261-265.
80. Louis, E.; El Ghoul, Z.; Vermeire, S.; Dall'ozzo, S.; Rutgeerts, P.; Paintaud, G.; Belaiche, J.; De Vos, M.; Van Gossum, A.; Colombel, J. F. and Watier, H. (2004) Association between polymoiphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19, 511-519.
81. Louis, E.; Pecters, M.; Franchimont, D.; Seidel, L.; Fontaine, F.; Demolin, G.; Croes, F.; Dupont, P.; Davin, L.; Omri, S.; Rutgeerts, P. and Belaiche, J. (2000) Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clin.Exp. Immunol. 119, 64-68.
82. Louis, E.; Vermeire, S.; Rutgeerts, P.; De Vos, M.; Van Gossum, A.; Pescatore, P.; Fiasse, R.; Pelckmans, P.; Reynaert, H.; D'haens, G.; Malaise, M. and Belaiche, J. (2002) A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37, 818-824.
83. Machida, H.; Tsukamoto, K.; Wen, C. Y.; Shikuwa, S.; Isomoto, H.; Mizuta, Y.; Takeshima, F.; Murase, K.; Matsumoto, N.; Murata, I. and Kohno, S. (2005) Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene. World J. Gastroenterol. 11, 4833-4837.
84. Mahmud, N.; Molloy, A.; Mcpardin, J.; Corbally, R.; Whitehead, A. S.; Scott, J. M. and Weir, D. G. (1999) Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 45, 389-394.
85. Malchow, H.; Ewe, K.; Brandes, J. W.; Goebell, H.; Ehms, H.; Sommer, H. and Jesdinsky, H. (1984) European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86, 249-266.
86. Marinaki, A. M.; Ansari, A.; Duley, J. A.; Arenas, M.; Sumi, S.; Lewis, C. M.; Shobowale-Bakre El, M.; Escuredo, E.; Fairbanks, L. D. and Sanderson, J. D. (2004) Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14, 181-187.
87. Mascheretti, S.; Hampe, J.; Kuhbacher, T.; Herfatth, H.; Krawczak, M.; Folsch, U. R. and Schreiber, S. (2002) Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. 2, 127-136.
88. Mcgovern, D. P.; Travis, S. P.; Duley, J.; Shobowale-Bakre El, M. and Dalton, H. R. (2002) Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 122, 838-839.
89. Mendoza, J. L.; Urcelay, E.; Lana, R.; Martin, M. C.; Lopez, N.; Guijarro, L. G.; Mayol, J. A.; Taxonera, C.; De La Concha, E. G.; Pena, A. S. and Diaz-Rubio, M. (2007) MDRI polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflamm. Bowel Dis. 13, 585-590.
90. Negoro, K.; Kinouchi, Y.; Hiwatashi, N.; Takahashi, S.; Takagi, S.; Satoh, J.; Shimosegawa, T. and Toyota, T. (1999) Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 117, 1062-1068.
91. Neurath, M. F.; Kiesstich, R.; Teichgraber, U.; Fischer, C.; Hofmann, U.; Eichelbaum, M.; Galle, P. R. and Schwab, M. (2005) 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin. Gastroenterol. Hepatol. 3, 1007-1014.
92. Nielsen, J. N.; Larsen, T. B.; Fredholm, L.; Brandslund, I.; Munkholm, P. and Hey, H. (2000) Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with IBD. Gut 47, 456-457.
93. Ogura, Y.; Bonen, D. K.; Inohara, N.; Nicolae, D. L.; Chen, F. F.; Ramos, R.; Britton, H.; Moran, T.; Karaliuskas, R.; Duerr, R. H.; Achkar, J. P.; Brant, S. R.; Bayless, T. M.; Kirschner, B. S.; Hanauer, S. B.; Nunez, G. and Cho, J. H. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606.
94. Ohtani, T.; Hiroi, A.; Sakurane, M. and Furukawa, F. (2003) Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. Br. J. Dermatol. 148, 1035-1039.
95. Onnie, C. M.; Fisher, S. A.; Pattni, R.; Sanderson, J.; Forbes, A.; Lewis, C. M. and Mathew, C. G. (2006) Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. Inflamm. Bowel Dis. 12, 263-271.
96. Oren, R.; Arber, N.; Odes, S.; Moshkowitz, M.; Keter, D.; Pomeranz, L; Ron, Y.; Reisfeld, I.; Broide, E.; Lavy, A.; Fich, A.; Eliakim, R.; Patz, J.; Bardan, E.; Villa, Y. and Gilat, T. (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110, 1416-1421.
97. Osterman, M. T.; Kundu, R.; Lichtenstein, G. R. and Lewis, J. D. (2006) Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130, 1047-1051
98. Palmieri, O.; Latiano, A.; Valvano, R.; D'inca, R.; Vecchi, M.; Sturniolo, G. C.; Saibeni, S.; Bossa, F.; Latiano, T.; Devoto, M.; Andriulli, A. and Annese, V. (2005) Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment. Pharmacol. Ther. 22, 1129-1138.
99. Paoluzi, O. A.; Pica, R.; Marcheggiano, A.; Crispino, P.; Iacopini, F.; Iannoni, C.; Rivera, M. and Paoluzi, P. (2002) Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther. 16, 1751-1759.
100. Papa, A.; De Stefano, V.; Danese, S.; Chiusolo, P.; Persichilh, S.; Casorelti, I.; Zappacosta, B.; Giardina, B.; Gasbarrini, A.; Leone, G. and Gasbarrini, G. (2001) Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am. J Gastroenterol. 96, 2677-2682.
101. Parsi, M. A.; Achkar, J. P.; Richardson, S.; Katz, J.; Hammel, J. P.; Lashner, B. A. and Brzezinski, A. (2002) Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123, 707-713.
102. Pawlik, A.; Wrzesniewska, J.; Fiedorowicz-Fabrycy, I. and Gawronska-Szklarz, B. (2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 42, 496-503.
103. Pettersson, B.; Almer, S.; Albertioni, F.; Soderhall, S. and Peterson, C. (2002) Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther. Drug Monit. 24, 351-358.
104. Pierik, M.; Rutgeerts, P.; Vlietinck, R. and Vermeire, S. (2006) Pharmacogenetics in inflammatory bowel disease. World J. Gastroenterol. 12, 3657-3667.
105. Pierik, M.; Vermeire, S.; Steen, K. V.; Joossens, S.; Claessens, G.; Vlietinck, R. and Rutgeerts, P. (2004) Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment. Pharmacol. Ther. 20, 303-310.
106. Poppe, D.; Tiede, L; Fritz, G.; Becker, C.; Bartsch, B.; Wirtz, S.; Strand, D.; Tanaka, S.; Galle, P. R.; Bustelo, X. R. and Neurath, M. F. (2006) Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176, 640-651.
107. Potocnik, U.; Ferkolj, I.; Glavac, D. and Dean, M. (2004) Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 5, 530-539.
108. Present, D. H.; Meltzer, S. J.; Krumholz, M. P.; Wolke, A. and Korelitz, B. I. (1989) 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. 111, 641-649.
109. Priest, V. L.; Begg, E. J.; Gardiner, S. J,; Frampton, C. M.; Gearry, R. B.; Barclay, M. L.; Clark, D. W. and Hansen, P. (2006) Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 24, 767-781.
110. Ranganathan, P. and Mcleod, H. L. (2006) Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 54, 1366-1377.
111. Reuther, L.O.; Sonne, J.; Larsen, N. E.; Larsen, B.; Christensen, S.; Rasmussen, S. N.; Tofteng, F.; Haaber, A.; Johansen, N.; Kjeldsen, J. and Schmiegelow, K. (2003) Pharmacological monitoring of azathioprine therapy. Scand. J. Gastroenterol. 38, 972-977.
112. Ricart, E.; Taylor, W. R.; Loftus, E. V.; O'kane, D.; Weinshilbourn, R. M.; Tremaine, W. J.; Harmsen, W. S.; Zinsmeister, A. R. and Sandborn, W. J. (2002) N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am. J Gastroenterol. 97, 1763-1768.
113. Robien, K.; Boynton, A. and Ulrich, C. M. (2005) Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 6, 673-689.
114. Roblin, X.; Serre-Debeauvais, F.; Phelip, J. M.; Bessard, G. and Bonaz, B. (2003) Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment. Pharmacol. Ther. 18, 917-925.
115. Rodrigues-Lima, F. and Dupret, J. M. (2004) Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non genetic factors. Curr. Pharm. Des. 10, 2519-2524.
116. Rutgeerts, P.; Sandborn, W. J.; Feagan, B. G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S. B.; Lichtenstein, G. R.; De Villiers, W. J.; Present, D.; Sands, B. E. and Colombel, J. F. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476.
117. Rutgeerts, P.; Van Assche, G. and Vermeire, S. (2006) Review article: Infliximab therapy for inflammatory bowel disease - seven years on. Aliment. Pharmacol. Ther. 23, 451-463.
118. Salavaggione, O. E.; Wang, L.; Wiepert, M.; Yee, V. C. and Weinshilboum, R. M. (2005) Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet. Genomics 15, 801-815.
119. Sandborn, W. J. (2001) Rational dosing of azathioprine and 6-mercaptopurine. Gut 48, 591-592.
120. Sanderson, J.; Ansari, A.; Marinaki, T. and Duley, J. (2004) Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann. Clin. Biochem. 41, 294-302.
121. Schaeffeler, E.; Eichelbaum, M.; Reinisch, W.; Zanger, U. M. and Schwab, M. (2006) Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum. Mutat. 27, 976.
122. Schaeffeler, E.; Fischer, C.; Brockmeier, D.; Wernet, D.; Moerike, K.; Eichelbaum, M.; Zanger, U. M. and Schwab, M. (2004) Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14, 407-417.
123. Schreiber, S.; Nikolaus, S. and Hampe, J. (1998) Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42, 477-484.
124. Schwab, M. and Klotz, U. (2001) Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin. Pharmacokinet. 40, 723-751.
125. Schwab, M.; Schaeffeler, E.; Marx, C.; Fromm, M. F.; Kaskas, B.; Metzler, J.; Stange, E.; Herfarth, H.; Schoelmerich, J.; Gregor, M.; Walker, S.; Cascorbi, I.; Roots, I.; Brinkmann, U.; Zanger, U. M. and Eichelbaum, M. (2003) Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124, 26-33.
126. Schwab, M.; Schaeffeler, E.; Marx, C.; Zanger, U.; Aulitzky; W. and Eichelbaum, M. (2001) Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology 121, 498-499.
127. Schwahn, B. and Rozen, R. (2001) Polymorphisms in the methylenctetrahydrofolate reductase gene: clinical consequences. Am. J. Pharmacogenomics 1, 189-201.
128. Seidman, E. G. (2003) Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev. Gastroenterol. Disord. 3, S30-S38.
129. Shastri, S.; Dubinsky, M. C.; Fred Poordad, F.; Vasiliaukas, E. A. and Geller, S. A. (2004) Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch. Pathol. Lab. Med. 128, 49-53.
130. Singleton, J. W.; Law, D. H.; Kelley, M. L., Jr.; Mekhjian, H. S. and Sturdevant, R. A. (1979) National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 77, 870-882.
131. Summers, R. W.; Switz, D. M.; Sessions, J. T., Jr.; Becktel, J. M.; Best, W. R.; Kern, F., Jr. and Singleton, J. W. (1979) National Cooperative Crohn's Disease Study: results ofdrug treatment. Gastroenterology 77, 847-869.
132. Szumlanski, C. L. and Weinshilboum, R. M. (1995) Sulphasalazine ihibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 39, 456-459.
133. Tanaka, E.; Taniguchi, A.; Urano, W.; Nakajima, H.; Matsuda, Y.; Kitamura, Y.; Saito, M.; Yamanaka, H.; Saito, T. and Kamatani, N. (2002) Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J. Rheumatol. 29, 2492-2499.
134. Tao, Y.; Williams-Skipp, C. and Scheinman, R. I. (2001) Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transtepression of NF-kappa B and induction of apoptosis. J. Biol. Chem. 276, 2329-2332.
135. Targan, S. R.; Hanauer, S. B.; Van Deventer, S. J.; Mayer, L.; Present, D. H.; Braakman, T.; Dewoody, K. L.; Schaible, T. F. and Rutgeerts, P. J. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337, 1029-1035.
136. Taylor, K. D.; Plevy, S. E.; Yang, H.; Landers, C. J.; Barry, M. J.; Rotter, J. I. and Targan, S. R. (2001) ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in, Crohn's disease. Gastroenterology 120, 1347-1355.
137. Teshima, D.; Hino, B., Makino, K.; Yano, T.; Itoh, Y.; Joh, Y.; Iida, M. and Oishi, R. (2003) Sulphasalazine-induced leucopenia in a patient with renal dysfunction. J. Clin. Pharm. Ther. 28, 239-242.
138. Tiede, I.; Fritz, G.; Strand, S.; Poppe, D.; Dvorsky, R.; Strand, D.; Lehr, H. A.; Wirtz, S.; Becker, C.; Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; Galle, P. R.; Ahmadian, M. R. and Neurath, M. F. (2003) CD218-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111, 1133-1145.
139. Urcelay, E.; Mendoza, J. L.; Martinez, A.; Fernandez, L.; Taxonera, C.; Diaz-Rubio, M. and De La Concha, E. G. (2005) IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J. Gastroenterol. 11, 1187-1192.
140. Van Den Brande, J. M.; Braat; H.; Van Den Brink, G. R.; Versteeg, H. H.; Bauer, C. A.; Hoedemaeker, I.; Van Montfrans, C.; Hommes, D. W.; Peppelenbosch, M. P. and Van Deventer, S. J. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-1785.
141. Van Dieren, J. M.; Kuipers, E. J.; Samsom, J. N.; Nieuwenhuis, E. E. and Van Der Woude, C. J. (2006) Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm. Bowel Dis. 12, 311-327.
142. Van Dieren, J. M.; Van Vuuren, A. J.; Kusters, J. G.; Nieuwenhuis, E. E.; Kuipers, E. J. and Van Der Woude, C. J. (2005) ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 54, 1664.
143. Vermeire, S.; Louis, E.; Carbonez, A.; Van Assche, G.; Noman, M.; Belaiche, J.; De Vos, M.; Van Gossum, A.; Pescatore, P.; Fiasse, R.; Pelckmans, P.; Reynaert, H.; D'haens, G. and Rutgeerts, P. (2002a) Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am. J. Gastroenterol. 97, 2357-2363.
144. Vermeire, S.; Louis, E.; Rutgeerts, P.; De Vos, M.; Van Gossum, A.; Belaiche, J.; Pescatore, P.; Fiasse, R.; Pelckmans, P.; Vlietinck, R.; Merlin, F.; Zouali, H.; Thomas, G.; Colombel, J. F. and Hugot, J. P. (2002b) NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123, 106-111.
145. Volk, E. L.; Farley, K. M.; Wu, Y.; Li, F.; Robey, R. W. and Schneider, E. (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62, 5035-5040.
146. Von Ahsen, N.; Armstrong, V. W.; Behrens, C.; Von Tirpitz, C.; Stallmach, A.; Herfarth, H.; Stein, J.; Bias, P.; Adler, G.; Shipkova, M.; Oellerich, M.; Kruis, W.; Reinshagen, M. and Schutz, E. (2005) Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study dropouts under azathioprine therapy in a prospective Crohn disease study. Clin. Chem. 51, 2282-2288.
147. Wallace, C. A. and Sherry, D. D. (1995) A practical approach to avoidance of methotrexate toxicity. J. Rheumatol. 22, 1009-1012.
148. Wehkamp, J. and Stange, E. F. (2006) Paneth cells and the innate immune response. Curr. Opin. Gastroenterol. 22, 644-650.
149. Weinshilboum, R. M. and Sladek, S. L. (1980) Mercaptopurine pharmaco-genetics: monogenic inheritance of erythrocyte thiopurine methyl-transferase activity. Am. J. Hum. Genet 32, 651-662.
150. Wellcome Trust Case Control Consortium. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145), 661-678.
151. Weisman, M. H.; Furst, D. E.; Park, G. S.; Kremer, J. M.; Smith, K. M.; Wallace, D. J.; Caldwell, J. R. and Dervieux, T. (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 54, 607-612.
152. Whetstine, J. R.; Gifford, A. J.; Witt, T.; Liu, X. Y.; Flatley, R. M.; Norris, M.; Haber, M.; Taub, J. W.; Ravindranath, Y. and Matherly, L. H. (2001) Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin. Cancer Res. 7, 3416-3422.
153. Willot, S.; Vermeire, S.; Ohresser, M.; Rutgeerts, P.; Paintaud, G.; Belaiche, J.; De Vos, M.; Van Gossum, A.; Franchimont, D.; Colombel, J. F.; Watier, H. and Louis, E. (2006) No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet. Genomics 16, 37-42.
154. Winter, J.; Walker, A.; Shapiro, D.; Gaffney, D.; Spooner, R. J. and Mills, P. R. (2004) Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 20, 593-599.
155. Wright, S.; Sanders, D. S.; Lobo, A. J. and Lennard, L. (2004) Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 53, 1123-1128.
156. Yokagawa, K.; Nakaharu, T.; Ishizaki, J.; Ozaki, E.; Takeda, Y.; Mabuchi, H.; Matsushita, R.; Kimura, K.; Nakashima, E.; Ichimura, F. and Miyamoto, K. (2001) Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine. Int. J. Pharm. 229, 183-191.
157. Zelinkova, Z.; Derijks, L. J.; Stokkers,, P. C.; Vogels, E. W.; Van Kampen, A. H.; Curvers, W. L.; Cohn, D.; Van Deventer, S. J. and Hommes, D. W. (2006) Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 4, 44-49.
158. Zeng, H.; Lin, Z. P. and Sartorelli, A.C. (2004) Resistance to purine and pyrimidine nucleoside and nucleobase, analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. Biochem. Pharmacol. 68, 911-921.